Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Healthcare.
Press releases published on May 19, 2025

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase …

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. …

Medical Learning Institute Inc Launches reelCE™, a Social-First Approach to Earning Continuing Education Credit
SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) -- Medical Learning Institute Inc (MLI), a non-profit jointly accredited continuing education (CE) provider, today announced the launch of reelCE™, enabling busy healthcare providers to earn CE credits by …

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in …

Dentsply Sirona to Participate in the 2025 Stifel Jaws & Paws Conference
CHARLOTTE, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 2025 Stifel Jaws …

XORTX Announces USD $3 Million Offering
CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive …

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA …

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such …

Teleflex Publishes 2024 Global Impact Report
WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans …

Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia
DIEPENBEEK, Belgium, May 19, 2025 (GLOBE NEWSWIRE) -- Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first …

Lifeward to Present at Sidoti Virtual Investor Conference on May 21
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation …

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive …

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva …

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures
May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D …

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy
LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global …

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May 19, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - …

AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN BREVET CHINOIS PROTÉGEANT LE MASITINIB DANS LE TRAITEMENT DU COVID-19 JUSQU'EN 2041, AJOUTANT AINSI UNE INDICATION SUPPLÉMENTAIRE BÉNÉFICIANT D'UNE PROTECTION À LONG TERME DE LA PROPRIÉTÉ INTELLECTUELLE Paris, 19 …